Litigation Details for NOVARTIS PHARMACEUTICALS CORPORATION v. ACTAVIS LLC (D.N.J. 2013)
✉ Email this page to a colleague
NOVARTIS PHARMACEUTICALS CORPORATION v. ACTAVIS LLC (D.N.J. 2013)
| Docket | See Plans and Pricing | Date Filed | 2013-02-20 |
| Court | District Court, D. New Jersey | Date Terminated | 2013-05-22 |
| Cause | 35:271 Patent Infringement | Assigned To | Susan Davis Wigenton |
| Jury Demand | Defendant | Referred To | Madeline Cox Arleo |
| Patents | 6,926,907; 7,932,241; 8,052,987; 8,324,189 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in NOVARTIS PHARMACEUTICALS CORPORATION v. ACTAVIS LLC
The small molecule drugs covered by the patents cited in this case are See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , and See Plans and Pricing .
Details for NOVARTIS PHARMACEUTICALS CORPORATION v. ACTAVIS LLC (D.N.J. 2013)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2013-02-20 | 1 | . 7,932,241 (“the ‘241 patent”) directed to certain approved presentations for zoledronic acid. 5. Upon…Novartis’ patent rights can be enforced 4. The three patents awarded to Novartis by the U.S. Patent and Trademark…are: U.S. Patent No. 8,324,189 (“the ‘189 patent”) directed to oncology methods, U.S. Patent No. 8,052,987…ACTION 2. This is an action for patent infringement under the patent laws of the United States, Title…987 patent”) directed to methods for treating abnormally increased bone turnover, and U.S. Patent No. | External link to document | |
| 2013-03-27 | 146 | Exhibit 2 | one Pozen patent (U.S. Patent 6,926,907—“the ‘907 patent”) and five AstraZeneca patents (not at issue… responses with regard to the ‘907 patent only. The ‘907 patent has 55 claims. On November 17, 2011…907 patent. Subsequently, Plaintiffs further narrowed their asserted claims of the ‘907 patent to …VIMOVO® drug prior to the expiration of Plaintiffs’ patents. Id. DRL is the first ANDA filer for…dkt. nos. 41 and 82. A. The ‘907 Patent Plaintiffs seek leave to amend their | External link to document |
| 2013-04-30 | 225 | primarily on the assertion of U.S. Patent No. 7,932,241 (“the ’241 patent”) in both the 2012 Case and …U.S. Patent No. 8,052,987 (“the ’987 patent”) and U.S. Patent No. 8,324,189 (“the ’189 patent”), which…and the February 2013 Case. The ’241 patent is the only patent from which Novartis asserted claims in…which are method of use patents asserted in the 2013 Cases, the ’241 patent is directed to the packaging…to improperly skirt the Local Patent Rules and revive the ’987 patent in the 2012 Case. Wockhardt is | External link to document | |
| 2013-05-13 | 236 | respect to U.S. Patent Nos. 7,932,241 and 8,052,987. Hospira alleged that these patents are invalid, …must include, among other things, the patent number of any patent that claims the drug or a method of… THE ’241 PATENT 14. The ’241 patent was issued on April 26, 2011, to…of using” zoledronic acid and is a patent for which a claim of patent infringement could reasonably … THE ’987 PATENT 20. The ’987 patent was issued on November 8, 2011, | External link to document | |
| 2013-05-13 | 237 | Novartis sued Wockhardt on U.S. Patent No. 8,052,987 (“the ’987 patent”) in Count II of the 2012 Case…fact that Novartis now has patent disputes regarding the ’987 patent with additional defendants …avoid this Court’s Local Patent Rules by re-asserting the ’987 patent in a new case. Perhaps because… claims of the ’987 patent, thereby waiving its ability to assert that patent against Wockhardt in… Novartis was aware that U.S. Patent No. 8,324,189 (“the ’189 patent”) had been allowed, and Novartis | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
